KalVista Pharmaceuticals, Inc. (KALV)

Over the past six months, KalVista Pharmaceuticals' stock has experienced several notable events. Between January 13, 2025, and January 9, 2026, the share price increased by 123.40%. The FDA approval of EKTERLY in 2025 was a significant catalyst for the company. In Q3 2025, the company reported a revenue beat, exceeding analyst forecasts by 90.93%, which led to a 5.42% rise in the stock price. Further positive news included the approval of EKTERLY in Japan in December 2025 and strong launch momentum in the US and Germany, with 1,318 patient start forms received in the US through December 2025. Analyst firms have also shown strong interest, with some boosting price targets. More recently, the stock has risen by 6.57% compared to the previous week, though it experienced a -2.67% fall over the last month. Insider selling of company stock has also been reported.

KalVista Pharmaceuticals has noted that fundamental demand has remained strong, with some effects from seasonal variability since the launch of EKTERLY in July 2025. Historically, implied volatility for KALV stock has tended to rise most significantly in December and decline to its lowest levels in November. While this indicates some seasonal patterns in market perception and trading activity, specific detailed information on the seasonality of demand for their pharmaceutical products and services is not extensively detailed.

KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with unmet medical needs. It operates within the Medical sector, specifically in the Biotechnology and Pharmaceutical Preparations industries, focusing on oral therapies for rare diseases like hereditary angioedema (HAE) and diabetic macular edema (DME). Its major product is EKTERLY (sebetralstat), the first and only FDA-approved oral on-demand treatment for HAE. KalVista is also developing Factor XIIa, an oral inhibitor for the prophylactic treatment of HAE, currently in preclinical trials, and orally disintegrating tablet formulations for HAE, including KONFIDENT-KID for pediatric use and KONFIDENT-S for adolescent and adult patients.

KalVista Pharmaceuticals is headquartered in Cambridge, Massachusetts, with its corporate office in Framingham, Massachusetts. The company also has operations in the United Kingdom, Utah, and Switzerland. EKTERLY has been launched in the United States and Germany, and received marketing and manufacturing approval in Japan in December 2025. KalVista plans to expand EKTERLY into other major markets during 2026 and has partnered with Multicare Pharma to commercialize sebetralstat in Latin America.

In the past year, KalVista Pharmaceuticals' brand reputation has been positively impacted by the FDA approval and successful launch of EKTERLY. News sentiment for the company has been reported at a score of 0.66, indicating a generally positive outlook. The strong demand for EKTERLY and positive feedback from patients and providers have further contributed to a favorable reputation. The company's commitment to addressing unmet medical needs in rare diseases, particularly HAE, underpins its brand image.

KalVista Pharmaceuticals' ownership is predominantly held by institutional investors, who collectively held approximately 61.60% of the company's stock as of July 2025, and 110.25% as of January 2026. Major institutional shareholders include VR Adviser, LLC, Tang Capital Management Llc, Frazier Life Sciences Management, L.P., Suvretta Capital Management, Llc, Capital World Investors, SMALLCAP WORLD FUND INC Class A, BlackRock, Inc., Vanguard Group Inc, Millennium Management Llc, and Woodline Partners LP. Insider ownership stands at a smaller percentage, ranging from 1.31% to 4.30%.